JP2023521667A5 - - Google Patents

Info

Publication number
JP2023521667A5
JP2023521667A5 JP2022560294A JP2022560294A JP2023521667A5 JP 2023521667 A5 JP2023521667 A5 JP 2023521667A5 JP 2022560294 A JP2022560294 A JP 2022560294A JP 2022560294 A JP2022560294 A JP 2022560294A JP 2023521667 A5 JP2023521667 A5 JP 2023521667A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
subject
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025495 external-priority patent/WO2021202948A2/en
Publication of JP2023521667A publication Critical patent/JP2023521667A/ja
Publication of JP2023521667A5 publication Critical patent/JP2023521667A5/ja
Priority to JP2026011981A priority Critical patent/JP2026086494A/ja
Pending legal-status Critical Current

Links

JP2022560294A 2020-04-04 2021-04-02 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 Pending JP2023521667A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026011981A JP2026086494A (ja) 2020-04-04 2026-01-28 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063005251P 2020-04-04 2020-04-04
US63/005,251 2020-04-04
US202063037838P 2020-06-11 2020-06-11
US63/037,838 2020-06-11
US202063086921P 2020-10-02 2020-10-02
US63/086,921 2020-10-02
PCT/US2021/025495 WO2021202948A2 (en) 2020-04-04 2021-04-02 Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026011981A Division JP2026086494A (ja) 2020-04-04 2026-01-28 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用

Publications (2)

Publication Number Publication Date
JP2023521667A JP2023521667A (ja) 2023-05-25
JP2023521667A5 true JP2023521667A5 (cg-RX-API-DMAC7.html) 2024-04-10

Family

ID=75625685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022560294A Pending JP2023521667A (ja) 2020-04-04 2021-04-02 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用
JP2026011981A Pending JP2026086494A (ja) 2020-04-04 2026-01-28 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026011981A Pending JP2026086494A (ja) 2020-04-04 2026-01-28 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用

Country Status (4)

Country Link
US (1) US20230174674A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126219A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023521667A (cg-RX-API-DMAC7.html)
WO (1) WO2021202948A2 (cg-RX-API-DMAC7.html)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
ES2905545T3 (es) * 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102011156B1 (ko) * 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
EP4234583A3 (en) * 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
DK2946206T3 (en) * 2013-01-20 2019-04-15 Dyax Corp EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS
JP2016513682A (ja) * 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
CN105873951A (zh) * 2013-10-21 2016-08-17 戴埃克斯有限公司 用于确定血浆激肽释放酶系统生物标记的试验
CN110658337B (zh) * 2013-10-21 2023-06-16 武田药品工业株式会社 自身免疫性疾病的诊断和治疗
ES3065185T3 (en) * 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL247942B (en) * 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
IL314752A (en) * 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co Metabolite biomarkers for diseases associated with the contact activation system

Similar Documents

Publication Publication Date Title
TWI241913B (en) Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
US7531164B2 (en) Preventing bacterial or viral infectivity and composition containing infection preventing additive
TW200528104A (en) Combination therapy for hcv infection
CN106535895A (zh) 丁型肝炎病毒感染的治疗
WO2022039619A1 (ru) Противовирусное средство для комбинированной терапии covid-19 (sars-cov-2)
JP2007501806A (ja) ウィルス感染を治療する方法
JP2016153402A (ja) C型肝炎ウイルス感染症の新規治療
CN118873497A (zh) 盐酸米托蒽醌脂质体在治疗乳腺癌中的用途
Afdhal et al. FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA: LB-3
Lawitz et al. 1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS
US11497747B2 (en) Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections
CN117442704A (zh) 一种治疗前列腺癌的药物组合及其应用
JP2024505482A (ja) Cd73を上方調節することができる薬剤及びグルココルチコイドの順次投与による疾患の治療
WO2021246989A1 (en) A combination of camostat mesylate and umifenovir hydrochloride
JP2014509628A (ja) C型肝炎ウイルス感染症を治療するためのアリスポリビル
CA2614639C (en) Pharmaceutical composition for treatment of blood clotting disorder
Leav et al. Safety and pharmacokinetics of a novel human monoclonal antibody directed against the E2 glycoprotein of hepatitis C virus (MBL-HCV1) in healthy volunteers
US20160184446A1 (en) Method of inhibiting body cavity fluid accumulation
Hoque Literature review of prospective drugs for COVID-19
US20230210890A1 (en) Compositions and methods of treating covid-19 with heparin or other negatively charged molecules
HK40104643A (en) Treatment of diseases with sequential administration of an agent capable of up-regulating cd73 and glucocorticoids
TW201110976A (en) Medicinal agent and method for treatment of intractable chronic hepatitis c
JP2001516725A (ja) 慢性C型肝炎症の処置のためのIFN−αとアマンタジンの使用
Rabe et al. Benefits of tiotropium/olodaterol over tiotropium alone in delaying clinically significant deterioration in patients with COPD
WO2025209478A1 (en) Methods of treatment warm autoimmune hemolytic anemia using sovleplenib